Blogs
Healthcare and Medtech Research Reports
Mar 20, 2020
Comprising less than 1% of all the adult malignancies, and inflicting pain in more than one body organ, the rarity and heterogeneity of sarcomas make it difficult to diagnose, treat and run a clinical trial resulting in efficient outcomes. The reason, why Soft tissue sarcoma market (STS market) has limited treatmen...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Newsletter/Whitepaper